These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11216334)

  • 41. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
    Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
    Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.
    Guze BH
    Pharmacoeconomics; 1996 May; 9(5):430-42. PubMed ID: 10160255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
    Crown WH
    Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
    Navarro R; Valler WE; Spangler M
    Med Interface; 1995 Aug; 8(8):114-9, 123. PubMed ID: 10144769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
    Panzarino PJ; Xuan J
    Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center.
    Singletary T; North DS; Weiss M; Marman G
    Am J Manag Care; 1997 Jan; 3(1):125-9. PubMed ID: 10169244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation.
    Tome MB; Isaac MT
    Int J Psychiatry Med; 1997; 27(4):377-90. PubMed ID: 9565733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
    Serrano-Blanco A; Pinto-Meza A; Suárez D; Peñarrubia MT; Haro JM;
    Acta Psychiatr Scand Suppl; 2006; (432):39-47. PubMed ID: 17087814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors.
    Donoghue J
    Acta Psychiatr Scand Suppl; 2000; 403():57-61. PubMed ID: 11019936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are SSRIs a cost-effective alternative to tricyclics?
    Hotopf M; Lewis G; Normand C
    Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study.
    Lee YC; Lin CH; Lin MS; Lin JW; Chang CH; Lai MS
    J Clin Psychopharmacol; 2013 Dec; 33(6):782-9. PubMed ID: 24091857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of cost savings to a state Medicaid program following a sertraline tablet-splitting program.
    Vuchetich PJ; Garis RI; Jorgensen AM
    J Am Pharm Assoc (2003); 2003; 43(4):497-502. PubMed ID: 12952314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.
    Taylor D
    Br J Psychiatry; 1995 Nov; 167(5):575-80. PubMed ID: 8564311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.